The MAS receptor (Mas1, encoded by the MAS1 gene) is a G-protein coupled receptor that functions as the primary receptor for Ang 1-7, mediating the protective, anti-inflammatory, vasodilatory, and metabolic arm of the RAA-system. Expressed ubiquitously across cardiovascular, renal, CNS, immune, adipose, and skeletal muscle tissues, it directly opposes the pathological signaling of Ang II through AT1 receptors, creating a fundamental yin-yang balance within the renin-angiotensin-aldosterone system.
Think of the RAA-system as a city's traffic control system with two competing headquarters. The AT1 receptor headquarters sends out orders to constrict roads, thicken walls, pile up sandbags (fibrosis), set off alarm bells (inflammation), and hoard supplies (Oxidative Stress). Meanwhile, the MAS receptor headquarters across town sends the exact opposite commands: widen the roads (vasodilation), send in repair crews to dismantle unnecessary barricades (anti-fibrotic), turn off false alarms (anti-inflammatory), and restore efficient energy flow (Insulin sensitivity). When ACE2 converts Ang II into Ang 1-7, it's like redirecting emergency calls from the panic-inducing AT1 headquarters to the calm, rational MAS headquarters—same starting alert, completely different response. In healthy physiology, both systems stay balanced, but in chronic disease (hypertension, diabetes, heart failure), the AT1 headquarters dominates, creating traffic jams, inflammation, and structural damage throughout the city. Activating MAS receptors—through Exercise, Polyphenols, or increasing ACE2 activity—is like giving power back to the rational headquarters, restoring order without suppressing the alarm system entirely.
Receptor activation cascade:
- Ligand binding: Ang 1-7 binds to MAS receptor (7-transmembrane G-protein coupled receptor)
- G-protein coupling: MAS couples primarily to Gαi/o proteins (inhibitory G-proteins)
- Intracellular signaling activation branches into multiple pathways:
Vasodilatory pathway:
- MAS activation → Gαi → activation of phosphoinositide 3-kinase (PI3K) → Akt phosphorylation → endothelial nitric oxide synthase (eNOS) phosphorylation at Ser1177 → increased Nitric Oxide (NO) production → cGMP elevation → smooth muscle relaxation → vasodilation
Anti-inflammatory pathway:
- MAS activation → inhibition of NF-κB nuclear translocation → reduced transcription of pro-inflammatory genes
- Suppression of MAPK pathways (ERK1/2, JNK, p38) → reduced IL-6, TNF-α, IL-1β production
- Downregulation of NADPH oxidase (NOX) → reduced Reactive Oxygen Species generation
Anti-fibrotic pathway:
- MAS activation → inhibition of TGF-beta signaling → reduced SMAD2/3 phosphorylation → decreased collagen type I and III synthesis
- Suppression of connective tissue growth factor (CTGF) → reduced extracellular matrix deposition
- Inhibition of Matrix metalloproteinases (MMPs) → prevention of pathological tissue remodeling
Metabolic pathway:
- MAS activation in Adipocytes → enhanced GLUT4 translocation → improved glucose uptake (insulin-independent mechanism)
- Activation of AMPK pathway → increased fatty acid oxidation
- Upregulation of Adiponectin secretion from adipose tissue
Neuroprotective pathway (CNS):
- MAS activation in Microglia → shift from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype
- Reduced microglial activation → decreased Neuroinflammation
- Enhanced neuronal survival through BDNF upregulation
graph TD
A[Ang 1-7] --> B[MAS Receptor]
B --> C["Gαi/o Coupling"]
C --> D[PI3K/Akt Pathway]
D --> E[eNOS Activation]
E --> F["↑ NO Production"]
F --> G[Vasodilation]
C --> H["↓ NF-κB Activity"]
H --> I["↓ IL-6, TNF-α, IL-1β"]
I --> J[Anti-inflammatory Effect]
C --> K["↓ TGF-β/SMAD"]
K --> L["↓ Collagen Synthesis"]
L --> M[Anti-fibrotic Effect]
C --> N["↑ GLUT4 Translocation"]
N --> O["↑ Glucose Uptake"]
O --> P[Improved Insulin Sensitivity]
C --> Q["Microglial M1→M2 Shift"]
Q --> R["↓ Neuroinflammation"]
R --> S[Neuroprotection]
The ACE2/Ang 1-7/MAS receptor axis represents the endogenous resolution system within RAA-system, directly relevant to every chronic inflammatory and metabolic condition in cPNI practice. This is the mechanistic basis for why ACE inhibitors (ending in "-pril": ramipril, enalapril, lisinopril) provide cardiovascular protection—they block ACE, reducing Ang II formation, which indirectly shifts balance toward ACE2-mediated Ang 1-7 production and MAS activation. However, ACE inhibitors don't directly increase ACE2 activity, which is why lifestyle interventions that upregulate ACE2 (aerobic Exercise, Intermittent fasting, Polyphenols like resveratrol and Quercetin) provide complementary benefits.
Clinical conditions where MAS receptor dysfunction is central:
- Hypertension: Reduced MAS signaling contributes to sustained vasoconstriction, endothelial dysfunction, and vascular remodeling. Upregulating MAS (via exercise, weight loss, polyphenol-rich diet) enhances NO-mediated vasodilation and can reduce blood pressure by 5-15 mmHg systolic.
- Type 2 Diabetes and Metabolic syndrome: MAS activation improves Insulin sensitivity through insulin-independent GLUT4 translocation, reduces visceral adipose inflammation, and increases Adiponectin (anti-inflammatory adipokine). This connects directly to Metamodel 3 (Metabolic System) and the concept of Insulin resistance as a protective-turned-pathological response.
- Chronic Kidney Disease: MAS receptor signaling is renoprotective—reducing glomerular inflammation, mesangial proliferation, and podocyte injury. Loss of MAS signaling accelerates progression from CKD stage 3 to stage 4.
- Heart failure: MAS activation reduces cardiac fibrosis, improves left ventricular function, and prevents pathological remodeling. Ang 1-7 supplementation (experimental) improves ejection fraction by ~8-12% in animal models.
- Neuroinflammation and Alzheimer's Disease: MAS receptor activation in brain tissue reduces microglial activation, oxidative stress, and amyloid-beta accumulation. This links to the Immune system in the brain concept and the protective role of ACE2 in CNS homeostasis.
- COVID-19 complications: SARS-CoV-2 downregulates ACE2 (via viral binding and internalization), shifting RAAS balance toward unopposed Ang II/AT1 signaling → acute inflammation, coagulopathy, and ARDS. MAS receptor agonists are being investigated as therapeutic interventions.
Evolutionary perspective: The ACE/Ang II/AT1 system evolved for acute survival responses—vasoconstriction, fluid retention, inflammation to fight infection. The ACE2/Ang 1-7/MAS system evolved to turn off those responses once the threat passes. Modern chronic stressors (sedentary behavior, processed foods, chronic psychological stress) keep the AT1 system chronically activated, while MAS signaling remains suppressed—a classic example of Evolutionary mismatch.
Intervention strategy: Upregulate MAS signaling through:
- Aerobic exercise (30+ minutes, 3-5x/week): increases ACE2 activity by ~40-60% in skeletal muscle and vascular endothelium
- Polyphenol intake: resveratrol (red wine, grapes), quercetin (onions, apples), EGCG (green tea) upregulate ACE2 expression
- Omega-3 fatty acids (EPA/DHA): enhance MAS receptor expression in cardiac tissue
- Statins (atorvastatin, rosuvastatin): increase ACE2 activity via non-lipid pleiotropic effects
- Intermittent fasting: transiently increases Ang 1-7 levels during fasted state
- MAS receptor is encoded by the MAS1 proto-oncogene, initially misidentified as a tumor-promoting gene before its RAAS function was discovered
- Expressed ubiquitously: cardiovascular system (endothelium, cardiomyocytes), kidneys (proximal tubules, podocytes), CNS (neurons, microglia, astrocytes), immune cells (macrophages, T cells), adipose tissue, skeletal muscle, pancreatic beta-cells
- Binding affinity: Ang 1-7 binds MAS with Kd ~10-50 nM (high affinity, low nanomolar range)
- MAS receptor activation increases Nitric Oxide production by 2-4 fold in endothelial cells within 15-30 minutes
- Anti-inflammatory threshold: MAS activation reduces IL-6 by ~40-60% and TNF-α by ~30-50% in inflammatory conditions
- Aerobic exercise increases skeletal muscle ACE2 activity by 40-60%, indirectly boosting Ang 1-7/MAS signaling
- Polyphenol intervention studies show 20-35% increase in ACE2 expression after 4-8 weeks of supplementation (resveratrol 150-300 mg/day, quercetin 500-1000 mg/day)
- MAS receptor knockout mice develop hypertension, insulin resistance, increased cardiac fibrosis, and enhanced susceptibility to ischemia-reperfusion injury
- COVID-19 severity correlates with reduced ACE2 expression and unopposed AT1 signaling—patients with pre-existing MAS upregulation (via exercise, healthy diet) show milder disease courses
- Ang 1-7 plasma levels in healthy individuals: 10-30 pg/mL; reduced to 5-15 pg/mL in metabolic syndrome and heart failure
- MAS receptor density is highest in cardiovascular and renal tissues, explaining why these organs benefit most from MAS activation
- Aldosterone (via Mineralocorticoid Receptor) suppresses MAS receptor expression—creating a feedforward loop favoring AT1 dominance in heart failure and CKD
- Ang 1-7 — the endogenous ligand that activates MAS receptor, produced by ACE2-mediated cleavage of Ang II
- ACE2 — the enzyme that produces Ang 1-7 from Ang II, shifting RAAS balance toward MAS receptor activation and away from AT1 signaling
- Ang II — MAS receptor signaling directly opposes Ang II/AT1 pathological effects (vasoconstriction, inflammation, fibrosis, oxidative stress)
- RAA-system — MAS receptor mediates the protective, anti-inflammatory, vasodilatory arm of the RAAS, balancing the pathological ACE/Ang II/AT1 axis
- ACE inhibitors — block ACE enzyme, reducing Ang II formation and indirectly shifting RAAS balance toward ACE2/Ang 1-7/MAS axis (though they don't directly increase ACE2 activity)
- Nitric Oxide — MAS receptor activation increases NO production via eNOS phosphorylation, causing vasodilation and improving endothelial function
- eNOS — MAS receptor activates eNOS through PI3K/Akt pathway, leading to NO production and vascular relaxation
- NF-κB — MAS receptor activation inhibits NF-κB nuclear translocation, reducing pro-inflammatory gene transcription
- IL-6 — MAS receptor activation reduces IL-6 production by 40-60% in inflammatory states, connecting to systemic inflammation resolution
- TNF-α — MAS receptor activation decreases TNF-α by 30-50%, contributing to anti-inflammatory effects
- TGF-beta — MAS receptor inhibits TGF-β signaling, preventing SMAD2/3 activation and reducing collagen synthesis (anti-fibrotic effect)
- Fibrosis — MAS receptor signaling is profoundly anti-fibrotic across multiple organs (heart, liver, lungs, kidneys) through TGF-β and CTGF inhibition
- Insulin resistance — MAS receptor activation improves insulin sensitivity through insulin-independent GLUT4 translocation and enhanced adiponectin secretion
- GLUT4 — MAS receptor promotes GLUT4 translocation to cell membrane in adipocytes and skeletal muscle, improving glucose uptake without requiring insulin
- Adiponectin — MAS receptor activation increases adiponectin secretion from adipose tissue, contributing to systemic insulin sensitization and anti-inflammatory effects
- Oxidative Stress — MAS receptor reduces reactive oxygen species (ROS) by inhibiting NADPH oxidase (NOX), protecting against oxidative damage
- Endothelial dysfunction — MAS receptor restores endothelial function through NO production, reduced inflammation, and improved vascular compliance
- Hypertension — MAS receptor activation causes vasodilation and blood pressure reduction, opposing AT1-mediated vasoconstriction
- Microglia — MAS receptor activation in CNS shifts microglia from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype, reducing neuroinflammation
- Neuroinflammation — MAS receptor signaling is neuroprotective, reducing microglial activation and protecting neurons from inflammatory damage
- Exercise — aerobic exercise increases ACE2 activity by 40-60%, indirectly boosting Ang 1-7 production and MAS receptor activation
- Polyphenols — resveratrol, quercetin, EGCG upregulate ACE2 expression and increase Ang 1-7/MAS signaling
- Metabolic syndrome — MAS receptor dysfunction contributes to insulin resistance, visceral adiposity, hypertension, and dyslipidemia; upregulation improves all components
- Heart failure — MAS receptor activation reduces cardiac fibrosis, improves left ventricular function, and prevents pathological remodeling
- Chronic Kidney Disease — MAS receptor is renoprotective, reducing glomerular inflammation, mesangial proliferation, and podocyte injury
- COVID-19 — SARS-CoV-2 downregulates ACE2, reducing Ang 1-7/MAS signaling and contributing to unopposed AT1-mediated inflammation and ARDS
- Intermittent fasting — transiently increases Ang 1-7 levels during fasted state, activating MAS receptor signaling
- BDNF — MAS receptor activation in CNS upregulates BDNF, contributing to neuroprotection and neuroplasticity